Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Silence Therapeutics (NASDAQ:SLN) Head-To-Head Analysis

Silence Therapeutics (NASDAQ:SLN) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations for Silence Therapeutics and Cyclacel Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1	0	6	0	2.71
Cyclacel Pharmaceuticals	0	1	1	0	2.50

Silence Therapeutics presently has a consensus target price of $45.00, suggesting a potential upside of 843.40%. Cyclacel Pharmaceuticals has a consensus target price of $11.00, suggesting a potential upside of 3,326.79%. Given Cyclacel Pharmaceuticals’ higher probable upside, analysts clearly believe Cyclacel Pharmaceuticals is more favorable than Silence Therapeutics.

Institutional and Insider Ownership

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 24.0% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Silence Therapeutics and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-342.00%	-62.81%	-33.89%
Cyclacel Pharmaceuticals	-18,150.00%	-1,901.11%	-188.23%

Valuation and Earnings

This table compares Silence Therapeutics and Cyclacel Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$16.25 million	8.79	-$53.82 million	($1.57)	-3.04
Cyclacel Pharmaceuticals	$74,000.00	27.27	-$22.56 million	($9.40)	-0.03

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Silence Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Summary

Silence Therapeutics beats Cyclacel Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.